Skip to main content
. 2022 Jan 1;45(5):941–961. doi: 10.1007/s40618-021-01704-3

Fig. 1.

Fig. 1

Prevalence of mild (white dots), mild–moderate (gray dots) and moderate (black dots) ED assessed by IIEF-6 questionnaire, in l-arginine (a) and placebo (b) groups at baseline; prevalence of mild–moderate (gray dots) and severe (black dots) vasculogenic ED assessed at dynamic PDU, in l-arginine (c) and placebo (d) groups at baseline